"Sequencing-grade" screening for BRCA1 variants by oligo-arrays
Alessandro Monaco1, Filippo Menolascina, Yingdong Zhao
1Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA. monacoal@cc.nih.gov
Journal of Translational Medicine
|November 1, 2008
Summary
A new oligonucleotide array method enables rapid, cost-effective genetic screening for disease predisposition. This high-throughput genotyping achieves accuracy comparable to direct sequencing, improving variant detection for various disorders.
Area of Science:
- Genomics
- Molecular Biology
- Biotechnology
Background:
- Genetic variants are crucial in disease predisposition.
- Current genetic screening methods can be slow, costly, and inefficient.
- There is a need for faster, more economical genetic variant screening tools.
Purpose of the Study:
- To develop and validate an oligonucleotide array-based process for gene-specific single nucleotide polymorphism (SNP) genotyping.
- To establish a cost-effective, high-throughput strategy for genetic screening.
- To assess the accuracy and efficiency of the developed method compared to direct sequencing.
Main Methods:
- Development of an oligonucleotide array-based genotyping process.
- Validation using the BRCA1 gene, a model for breast and ovarian cancer predisposition.
- Testing the system's ability to detect various genetic variants, including point mutations, insertions, and deletions, in heterozygous conditions.
Main Results:
- The developed oligonucleotide array process demonstrated high sensitivity and accuracy, comparable to direct sequencing.
- The method proved cost-effective and suitable for high-throughput genetic screening.
- The system successfully detected known and unknown variants, including point mutations, insertions, and deletions, without compromising sensitivity or specificity.
Conclusions:
- The oligonucleotide array-based genotyping process offers a fast, efficient, and less costly alternative for genetic variant screening.
- This technology can be applied to various genetic disorders and custom-designed for specific clinical conditions.
- The system is particularly advantageous for screening long genomic regions with infrequent but clinically relevant variants, significantly reducing time and cost.
